The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.00
Bid: 4.75
Ask: 5.25
Change: 0.00 (0.00%)
Spread: 0.50 (10.526%)
Open: 5.00
High: 5.00
Low: 4.875
Prev. Close: 5.00
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
25th Mar 202211:00 amRNSPrice Monitoring Extension
24th Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20224:41 pmRNSSecond Price Monitoring Extn
22nd Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20223:16 pmRNSPALOH study results published in JAMA Pediatrics
21st Mar 20229:05 amRNSSecond Price Monitoring Extn
21st Mar 20229:00 amRNSPrice Monitoring Extension
18th Mar 20224:41 pmRNSSecond Price Monitoring Extn
18th Mar 20224:36 pmRNSPrice Monitoring Extension
18th Mar 20222:05 pmRNSSecond Price Monitoring Extn
18th Mar 20222:00 pmRNSPrice Monitoring Extension
18th Mar 20222:00 pmRNSFirst NHS Deployments of Genedrive System for AIHL
17th Mar 20227:00 amRNSBoard appointment
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:35 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSFurther re Directorate Change
23rd Feb 20225:00 pmRNSDirector/PDMR Shareholding
23rd Feb 20229:05 amRNSSecond Price Monitoring Extn
23rd Feb 20229:00 amRNSPrice Monitoring Extension
23rd Feb 20227:00 amRNSUpdate on Point of Care Covid Test
15th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSNotice of Results
21st Jan 202211:05 amRNSSecond Price Monitoring Extn
21st Jan 202211:00 amRNSPrice Monitoring Extension
20th Jan 20224:40 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
10th Jan 20229:06 amRNSSecond Price Monitoring Extn
10th Jan 20229:00 amRNSPrice Monitoring Extension
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:01 pmRNSPrice Monitoring Extension
30th Dec 202111:20 amRNSResult of AGM
30th Dec 20219:05 amRNSSecond Price Monitoring Extn
30th Dec 20219:00 amRNSPrice Monitoring Extension
22nd Dec 202111:06 amRNSSecond Price Monitoring Extn
22nd Dec 202111:00 amRNSPrice Monitoring Extension
22nd Dec 20217:00 amRNSUK CTDA application for Genedrive® COV19-ID kit
20th Dec 20214:41 pmRNSSecond Price Monitoring Extn
20th Dec 20214:36 pmRNSPrice Monitoring Extension
20th Dec 20211:08 pmRNSDirector/PDMR Shareholding
20th Dec 20217:00 amRNSHolding(s) in Company
14th Dec 20212:06 pmRNSSecond Price Monitoring Extn
14th Dec 20212:00 pmRNSPrice Monitoring Extension
13th Dec 20214:41 pmRNSSecond Price Monitoring Extn
13th Dec 20214:35 pmRNSPrice Monitoring Extension
9th Dec 202111:06 amRNSSecond Price Monitoring Extn
9th Dec 202111:00 amRNSPrice Monitoring Extension
9th Dec 20219:05 amRNSSecond Price Monitoring Extn
9th Dec 20219:00 amRNSPrice Monitoring Extension
8th Dec 20214:40 pmRNSSecond Price Monitoring Extn
8th Dec 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.